Celgene is now part of Bristol-Myers Squibb creating a leading biopharma company positioned to help address the needs of patients with serious diseases.
From February 1, 2020, all new funding applications must be submitted through the Bristol-Myers Squibb Corporate Grants and Giving website. For Independent Medical Education (IME) and Scientific Advancement Grant (SAG) requests such as fellowships, investigator awards and closed/invite-only scientifically-based meetings, please refer to the Corporate Giving FAQ link below for more information.
To submit an application for an independent medical education (IME) grant, please visit: https://www.bms.com/about-us/responsibility/IME.html
To submit an application for a Scientific Advancement Grant (SAG), please visit: https://bms.com/about-us/responsibility/corporate-giving.html
Please refer to the following for more information:
• BMS Corporate Giving Guidelines: https://www.bms.com/about-us/responsibility/corporate-giving/giving-guidelines.html
• BMS Corporate Giving FAQs: https://www.bms.com/about-us/responsibility/corporate-giving/corporate-giving-faqs.html
• BMS-IME Integration Information: https://www.celgene.com/research-development/celgene-medical-affairs/medical-affairs-grants/independent-medical-education-grants/
If you have already submitted an application through Celgene systems and have not received a decision, please do not submit a duplicate application. Bristol-Myers Squibb will review all pending applications, and will get back to you as soon as possible with a decision.
Many thanks for your continued patience during this transition period.
As a result of the acquisition of Celgene by Bristol-Myers Squibb, and the divestiture of Otezla® to Amgen, funding requests related to Otezla® (dermatology, rheumatology and Behcet’s Disease) are no longer being accepted on Celgene’s funding portal.
As of Thursday, November 21, 2019, Amgen will accept related funding requests as follows: